A WORLD WITHOUT CANCER: WE’RE BRINGING IT CLOSER EVERY DAY

Despite all the advances the oncology community has seen since 1987 when we came to America, there are still too many cancer patients with unmet needs. That’s why, as a human health care company, we keep increasing our commitment to oncology. We won’t stop pursuing breakthroughs until the world is cancer-free. Please visit our clinical trials area for information about open Eisai oncology studies.

Explore how Eisai scientists discovered an ocean treasure that may help some cancer patients live longer.
click here for full prescribing information

KNOWLEDGE IS POWER FOR PEOPLE LIVING WITH CANCER. LEARN MORE ABOUT:

THYROID CANCER right arrow RENAL CELL CARCINOMA right arrow HEPATOCELLULAR CARCINOMA right arrow
oncology promo mobile oncology promo

HOW DOES OUR hhc MISSION INSPIRE ONCOLOGY BREAKTHROUGHS? HERE’S A REAL-WORLD EXAMPLE

When we first set out to develop a new anti-cancer agent, we didn’t sacrifice quality for speed. We concentrated on diseases with poor prognoses and few treatment options, regardless of the size of the patient populations. We prioritized how the compound would bind to certain targets implicated in the pathogenesis of the cancer.

Our determination to address patients' unmet medical needs drove us to synthesize a chemical process with millions of steps. Ultimately, it led us to develop a targeted agent.

We're now investigating that agent with Merck (known as MSD outside the United States and Canada) in combination with their anti-PD-1 therapy in different kinds of cancer in the hopes of reaching more patients in need. In fact, Eisai and Merck received three Breakthrough Therapy designations and one approval from the FDA.

We're evaluating the combination in 14 tumor types across 20 clinical trials:

  • Biliary tract cancer
  • Colorectal cancer
  • Endometrial carcinoma
  • Gastric cancer
  • Glioblastoma
  • Hepatocellular carcinoma
  • Melanoma
  • Non-small cell lung cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Renal cell carcinoma
  • Squamous cell carcinoma of the head and neck
  • Triple-negative breast cancer
  • Urothelial carcinoma

LEARN THE LATEST ON HOW WE’RE HELPING PEOPLE LIVING WITH CANCER

learn more

MISSION ACCEPTED: THE NEXT EVOLUTION OF IMMUNO-ONCOLOGY (I-O)

To date, “immuno-oncology” has been synonymous with one modality. Eisai’s aim is to show that other modalities — alone, in combination or in sequence with checkpoint inhibitors — may help to normalize or even enhance the immune microenvironment and enhance antitumor activity. This is what our pipeline has been designed to explore.

The same small molecule and translational medicine expertise that served as the foundation for Eisai Oncology's current portfolio is also powering the future of our oncology pipeline. Combined with our Big Data, human biology and cancer genomics capabilities, we are poised to expand immuno-oncology as we know it to usher in a new era of personalized cancer medicines.

OUR PIPELINE LEADS STRAIGHT TO THE FUTURE OF ONCOLOGY

We’re pursuing potential breakthroughs designed to:

  • Modulate the microenvironment of a broad range of tumors
  • Inhibit signaling pathways that play important roles to inactivate the immune system
  • Leverage cancer genomics to target cancer drivers, tumor resistance and immune evasion
find out what’s in our pipeline right now